Skip to content
Peptigraph home

Thymosin Alpha-1 for Liver: What the Evidence Shows

What human and animal studies show about Thymosin Alpha-1 for liver, how strong that evidence is, and what is still unproven.

Medical review pendingImmune modulatorUpdated
Strongest evidence
Human RCT
Human studies
1
with an outcome for liver, in our evidence file (PubMed search, 11 Oct 2026)
Animal studies
None found
with an outcome for liver, in our evidence file (PubMed search, 11 Oct 2026)
Studies we summarised
4
with an outcome for liver

Evidence for liver

Each row is an outcome related to liver from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Thymosin Alpha-1 for liver: outcomes in published studies
OutcomeResultStudy typeSource
Response rate37.5% (6 of 16) responded.Human RCTn = 16Internal medicine 2003, PMID 14606705
Low vs high doseThe low and high dose groups did not differ significantly.Human RCTn = 16Internal medicine 2003, PMID 14606705
All-cause mortalityPooled all-cause mortality was lower (RR 0.53) but certainty is very low.Meta-analysisn = 1349The Cochrane database of systematic reviews 2026, PMID 42713852
Histological improvement and quality of lifeLittle to no effect on quality of life or histology, with very low certainty.Meta-analysisn = 1349The Cochrane database of systematic reviews 2026, PMID 42713852
Virological response vs interferonSix months after treatment, odds of virological response were 3.71 times those with interferon alpha.Meta-analysisn = 199Antiviral research 2008, PMID 18078676
Sustained response in hepatitis BSeven randomized studies reported a higher sustained response than untreated controls with 6 months of 1.6 mg twice weekly.ReviewExpert review of anti-infective therapy 2004, PMID 15482167

Thymosin Alpha-1 and liver are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4Internal medicine 2003, PMID 14606705

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Viral hepatitis, the liver condition thymosin alpha 1 was tested in

MedlinePlus lists hepatitis A, B and C among the liver diseases caused by viruses.[5]

A Cochrane review included 10 randomised trials with 1349 participants in chronic hepatitis B, published between 1991 and 2018.[2]

The review's critical outcomes were all-cause mortality, serious adverse events and health-related quality of life.[2]

What the hepatitis B studies found

The Cochrane synthesis found a risk ratio of 0.72 for serious adverse events (5 studies, 1056 participants), with low-certainty evidence.[2]

Against interferon alpha, thymosin alpha-1's complete response odds were 0.54 at the end of 6 months of treatment and 2.69 at the end of follow-up.[3]

A small hepatitis B pilot reported a 37.5% response rate, with no statistically significant difference between its low and high dose groups.[1]

Patients in that pilot were randomised to 0.8 mg (low dose) or 1.6 mg (high dose) of thymosin alpha 1 and then dosed twice weekly for another 22 weeks.[1]

A review of randomised monotherapy studies said 6 months of treatment at 1.6 mg twice weekly gave a higher sustained response than no treatment.[4]

Tolerability in hepatitis populations

In a hepatitis B trial against interferon, thymosin alpha-1 was well tolerated and the only side effect was local discomfort at injection sites.[6]

In the hepatitis C pilot, no patient cleared HCV-RNA and the authors concluded the regimen was not effective.[7]

The Cochrane review notes only two of its trials mentioned comorbidities such as cirrhosis and acute-on-chronic liver failure.[2]

Other peptides people research for liver

All peptides for liver, compared

Common questions

Does Thymosin Alpha-1 help with liver?

The strongest study we summarise for liver is human rct evidence, across 4 studies with an outcome for liver. A trial result is not an approval; see the legal status.

Is Thymosin Alpha-1 approved for liver?

No. Thymosin Alpha-1 is not FDA approved for any use, including liver.

What is the best peptide for liver?

There is no single answer. Our liver overview compares each candidate by evidence grade and legal status rather than by popularity.

Does thymosin alpha 1 treat hepatitis B?

The Cochrane authors are not sure whether it reduces mortality or serious adverse events, and judge the certainty of the evidence very low for all outcomes except serious adverse events.[2]

Is thymosin alpha 1 effective for hepatitis C?

A small placebo-controlled trial concluded this regimen was not effective in chronic hepatitis C.[7]

More on Thymosin Alpha-1

Sources

  1. 1A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
  2. 2Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
  3. 3Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.Antiviral research · 2008PMID 18078676Accessed 2 Oct 2026
  4. 4Thymalfasin for the treatment of chronic hepatitis B.Expert review of anti-infective therapy · 2004PMID 15482167Accessed 2 Oct 2026
  5. 5Official web pageOfficial web page · web page
  6. 6A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.Hepatology (Baltimore, Md.) · 1996PMID 8855175Accessed 11 Oct 2026
  7. 7A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C.Liver · 1996PMID 8873009Accessed 11 Oct 2026

Found an error? Report a correction.